Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
about
Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cellsNovel therapies for metastatic castrate-resistant prostate cancer.Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerCorepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells.Tissue-selective regulation of androgen-responsive genesAdvances in androgen receptor targeted therapy for prostate cancerLigand-independent and tissue-selective androgen receptor inhibition by pyrvinium.Blockade of testicular and adrenal androgens in prostate cancer treatment.Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.Testosterone in prostate cancer: the Bethesda consensus.Androgen action and metabolism in prostate cancer.Improving selective androgen receptor modulator discovery and preclinical evaluation.11β-hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function.The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells.The role of transcription factors in prostate cancer and potential for future RNA interference therapy.The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer.Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerHuman castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling.Androgen receptor abnormalities in castration-recurrent prostate cancer.Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cellsMolecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate.ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.Paracrine Hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner.CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.Gene expression correlation analysis predicts involvement of high- and low-confidence risk genes in different stages of prostate carcinogenesis.
P2860
Q28288947-12DFBA48-D6C9-4EAC-A5CC-FC701465400DQ34249263-8D1EF3EB-E0E1-47C5-BFCA-904B4ADF265CQ34375823-225C5AA7-9AF6-476A-89DE-9953B049C105Q35685920-48A39E0D-843E-48C3-87C6-8FC96649FFAAQ35786826-A177FB6C-949C-4CF4-B26C-E4B0B9722277Q36029539-797DFCE3-EE2E-43DA-AE0E-173EBA01C555Q36530805-6CB4A9D5-0903-4F20-B953-843E7CCF508CQ36697482-DB7DAF4E-C35D-4890-BE0F-F930325AB717Q37337217-90F4B274-D2F4-4122-A300-AD84EF2C96FEQ37656304-6F34DC1F-4803-4915-A675-356D056186E0Q37829637-73909F8F-78EA-490A-A10E-5C6838AFB803Q37829693-804184AE-36E7-48BE-9E4E-9F258C0AEE34Q37845245-3157ED14-8C95-496D-87FA-31E7F01C1A78Q37947091-4DAF6EF9-1FAB-49EC-A7B2-A5DE61BEAB6EQ37963010-38013743-FA24-4AB7-92DF-1A4EB604D4F2Q37997571-944E98EB-A1B9-4E5D-AEF6-C55D1A2C66C6Q38088367-80C29B4B-94A2-4DFB-94B7-318EFEAD917BQ38156007-C2506ED5-E8A5-47EB-BDD4-6AEC709C058EQ38166575-8951603C-78D7-4CAC-93F3-4DFC08A007B7Q38198726-8CE74BC3-3D5A-4E7A-A38C-1562D862C754Q38223389-7BEBB55A-2EA9-499D-B325-5A703B47DC20Q38256395-06C491CF-6057-4A02-B379-2127A4673C3FQ38276818-46849C67-70D1-4F9B-A29F-AF98D09B8860Q39190804-A2678806-495A-4158-93F6-7956B7C4171DQ39301953-6DA3CE9A-692D-4DF9-8AEE-DE92399084D6Q39507379-721BFC76-FA5B-4EC3-ABBD-912F95D526DAQ39583449-F3551B41-E5B0-4702-B74D-2446F51709D3Q41886996-B9BC2E60-9E7F-4ECA-BC33-9A528AD71292Q42183706-2F8DDB5C-B540-4C97-8781-26CDB6C9622DQ42288618-ADD67AC1-5819-40AD-BBE3-DC458C130A5CQ42417359-195A5DA9-C091-4641-86A5-6D61434662FAQ44748964-A469C189-98C0-4917-B382-46FF74AB352DQ50943950-03C37FF4-BF1E-4594-A061-60C3441A6BFAQ51905999-0127925A-8414-4ECE-8212-104EB020F172
P2860
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Castration-resistant prostate ...... pathways in recurrent disease.
@en
Castration-resistant prostate ...... pathways in recurrent disease.
@nl
type
label
Castration-resistant prostate ...... pathways in recurrent disease.
@en
Castration-resistant prostate ...... pathways in recurrent disease.
@nl
prefLabel
Castration-resistant prostate ...... pathways in recurrent disease.
@en
Castration-resistant prostate ...... pathways in recurrent disease.
@nl
P2093
P2860
P1433
P1476
Castration-resistant prostate ...... pathways in recurrent disease.
@en
P2093
Bruce Montgomery
Elahe A Mostaghel
Peter S Nelson
P2860
P304
P356
10.1016/J.UROLONC.2009.03.016
P577
2009-05-01T00:00:00Z